Last updated: February 14, 2026
Overview of the Drug
NDC 70710-1241 is identified as empagliflozin, marketed under the brand name Jardiance by Boehringer Ingelheim and Eli Lilly. It is an oral sodium-glucose co-transporter 2 (SGLT2) inhibitor approved for the management of type 2 diabetes mellitus, heart failure, and certain kidney conditions.
Market Adoption and Key Competitors
The drug faces competition from other SGLT2 inhibitors, notably:
- Canagliflozin (Invokana) – Johnson & Johnson
- Dapagliflozin (Farxiga/Forxiga) – AstraZeneca
- Ertugliflozin (Steglatro) – Merck
In 2022, Jardiance maintained approximately 35% of the SGLT2 inhibitor market share in the U.S., influenced by its indications for both diabetes and heart failure with reduced ejection fraction (HFrEF).
Market Size and Growth
The global market for SGLT2 inhibitors was valued at approximately $7.2 billion in 2022, with a compound annual growth rate (CAGR) of approximately 15% projected through 2027. In the U.S., the diabetes segment alone represented around $4.2 billion in 2022, growing at a CAGR of almost 14%.
Key market drivers include:
- The expanding indications for heart failure and chronic kidney disease.
- Growing prevalence of type 2 diabetes and cardiovascular comorbidities.
- Favorable clinical outcomes compared to other antidiabetic agents.
Pricing Structure and Reimbursement Environment
The wholesale acquisition cost (WAC) for Jardiance in the U.S. ranges between $535 and $560 per month for a typical dose (based on available data from IQVIA). Actual patient costs vary depending on insurance coverage, discounts, and payer negotiations.
Comparison with competitors:
| Drug |
WAC per month |
Indications |
Approvals |
| Empagliflozin (Jardiance) |
~$550 |
Diabetes, HFrEF, CKD |
2014, expanded 2020 |
| Canagliflozin (Invokana) |
~$620 |
Diabetes, CKD |
2013 |
| Dapagliflozin (Farxiga) |
~$530 |
Diabetes, HFpEF, CKD |
2014 |
| Ertugliflozin (Steglatro) |
~$520 |
Diabetes |
2017 |
Pricing stability is influenced by the competitive landscape, patent protections, and potential biosimilar entry.
Patent Life and Market Exclusivity
Boehringer Ingelheim and Lilly's patent for empagliflozin provides exclusivity until approximately 2030-2032 in the U.S. and Europe. Patent expirations could introduce biosimilars or generics, likely resulting in price erosion of 20%-60% within the two years post-entry, based on historical precedents with similar drugs.
Regulatory and Reimbursement Outlook
Recent approvals for additional indications, like heart failure with preserved ejection fraction (HFpEF), broaden the market base. Reimbursement by Medicare, Medicaid, and private insurers favors access, but negotiated formulary placements impact final patient prices.
Future Market and Price Projections
Projected growth hinges on:
- Further expansion of indications (e.g., CKD, HFpEF).
- Clinical trial results confirming benefits in broad populations.
- Competitive dynamics, including potential biosimilar entry around 2030.
Here are the projections for the next five years:
| Year |
Estimated Global Market ($ billion) |
Expected Price Trend |
Key Drivers |
| 2023 |
8.2 |
Stable with slight decline |
Slight price compression, steady demand |
| 2024 |
9.4 |
5%-8% decline |
Entry of biosimilars in select markets, payer negotiations |
| 2025 |
10.8 |
5%-10% decline |
Increased competition, expanded indications |
| 2026 |
12.2 |
3%-6% decline |
Saturation in primary indications |
| 2027 |
13.5 |
Stabilization or slight decline |
Market maturation, biosimilar competition |
Risks to Market and Price
- Patent expiries could accelerate price declines.
- Regulatory delays or restrictions on expanding indications.
- Competitive innovations, such as oral agents or combination therapies.
- Reformulations or biosimilars entering the market at discounted prices.
Key Takeaways
- NDC 70710-1241, empagliflozin, remains a leading SGLT2 inhibitor in the evolving diabetes and heart failure market.
- Pricing ranges from approximately $520 to $560 per month, with insights pointing toward slight declines in coming years due to biosimilar competition.
- The global market is poised for growth driven by expanding indications and increased prevalence.
- Patent exclusivity extends into the early 2030s, providing pricing power until biosimilar entry.
- Market share will depend on successful indication expansion, clinical outcomes, and payer strategies.
FAQs
Q1: How does empagliflozin compare price-wise to its main competitors?
Empagliflozin costs about $530 to $560 monthly, slightly below dapagliflozin and ertugliflozin, but less than canagliflozin. Price differences are influenced by formulary negotiations and market positioning.
Q2: When can biosimilars or generics be expected to impact empagliflozin's prices?
Patent protections could expire around 2030-2032, with biosimilars entering the market within 1-2 years thereafter, potentially reducing prices by up to 50%.
Q3: What factors most influence empagliflozin's market share?
Clinical trial outcomes, indication approvals, formulary status, and competitive pricing primarily determine market penetration.
Q4: Are there upcoming regulatory approvals that could expand empagliflozin’s market?
Yes, approval for additional indications like heart failure with preserved ejection fraction is anticipated, broadening its use.
Q5: What are the main risks that could threaten the drug’s market position?
Patent expiration, generic competition, unfavorable regulatory decisions, and clinical trial failures are primary risks.
Sources
- IQVIA. "Pharmacovigilance Annual Review," 2022.
- FDA. "Drug Approvals and Indications," 2022-2023.
- MarketWatch. "SGLT2 Inhibitors Market Size," 2022.
- Evaluate Pharma. "Global Diabetes Drugs Market," 2022.
- Company SEC Filings and press releases.
